Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy

被引：0
作者：
Elena María Brozos-Vázquez
Roberto Díaz-Peña
Jorge García-González
Luis León-Mateos
Patricia Mondelo-Macía
María Peña-Chilet
Rafael López-López
机构：
[1] Complexo Hospitalario Universitario de Santiago de Compostela,Department of Medical Oncology
[2] Health Research Institute of Santiago (IDIS),Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet)
[3] Complexo Hospitalario Universitario de Santiago de Compostela,Facultad de Ciencias de la Salud
[4] Instituto de Salud Carlos III,Clinical Bioinformatics Area
[5] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC),undefined
[6] Universidad Autónoma de Chile,undefined
[7] Bioinformatics in Rare Diseases (BiER),undefined
[8] Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER),undefined
[9] Fundación Progreso y Salud (FPS),undefined
[10] Hospital Virgen del Rocío,undefined
[11] Institute of Biomedicine of Sevilla (IBiS,undefined
[12] CSIC,undefined
[13] Universidad de Sevilla),undefined
来源：
Cancer Immunology, Immunotherapy | 2021年 / 70卷
关键词：
Lung cancer; NSCLC; Liquid biopsy; Immunotherapy; CTC; cfDNA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Immunotherapy has been one of the great advances in the recent years for the treatment of advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that has benefited most from this approach. Currently, the only validated companion diagnostic test for first-line immunotherapy in metastatic NSCLC patients is testing for programmed death ligand 1 (PD-L1) expression in tumor tissues. However, not all patients experience an effective response with the established selection criteria and immune checkpoint inhibitors (ICIs). Liquid biopsy offers a noninvasive opportunity to monitor disease in patients with cancer and identify those who would benefit the most from immunotherapy. This review focuses on the use of liquid biopsy in immunotherapy treatment of NSCLC patients. Circulating tumor cells (CTCs), cell-free DNA (cfDNA) and exosomes are promising tools for developing new biomarkers. We discuss the current application and future implementation of these parameters to improve therapeutic decision-making and identify the patients who will benefit most from immunotherapy.
引用
收藏
页码：1177 / 1188
页数：11
相关论文
共 206 条
  • [1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
  • [2] Ferlay J(2014)Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009 Lung Cancer (Amsterdam, Netherlands) 86 22-28
  • [3] Soerjomataram I(2018)Treatment of advanced non-small cell lung cancer in 2018 JAMA Oncol 4 569-1426
  • [4] Houston KA(2016)Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Lancet (Lond, Engl) 387 1415-290
  • [5] Henley SJ(2019)Lung cancer and liquid biopsy: realities and challenges in routine clinical practice Arch Bronconeumol 55 289-264
  • [6] Li J(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-30202
  • [7] Doroshow DB(2020)Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations J Thorac Oncol S1556–0864 30198-135
  • [8] Herbst RS(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-1639
  • [9] Barlesi F(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-2426
  • [10] Mazieres J(2017)First-line nivolumab in stage IV or recurrent non–small-cell lung cancer N Engl J Med 376 2415-1550
12345678910